- In April 2023, Pfizer Inc. announced a strategic collaboration with Samsung Biologics to increase production capacity for biologic prescription drugs targeting oncology and inflammatory diseases. This move highlights Pfizer’s commitment to strengthening its global supply chain and improving access to critical therapies in underserved markets, particularly in Asia-Pacific and emerging regions
- In March 2023, Roche introduced a next-generation personalized cancer therapy, inavolisib, in Phase III clinical trials targeting breast cancer with PI3K mutations. This development showcases the company’s focus on precision medicine and innovation in the oncology prescription drug segment, which remains one of the highest-revenue-generating therapeutic areas globally
- In March 2023, Sanofi announced its acquisition of Provention Bio, Inc., a U.S.-based biopharmaceutical company focused on autoimmune diseases. This acquisition strengthens Sanofi’s prescription drug portfolio in the immunology space, particularly with the addition of TZIELD, the first and only approved drug to delay the onset of type 1 diabetes
- In February 2023, Johnson & Johnson launched a global access initiative for its long-acting HIV treatment cabotegravir through licensing agreements with generic manufacturers. This move is designed to increase access to affordable HIV medications in low- and middle-income countries, emphasizing the company’s focus on equitable healthcare through expanded prescription drug access
- January 2023, Eli Lilly and Company received FDA approval for its novel obesity treatment, tirzepatide, under the brand name Zepbound. As part of its expanding endocrinology portfolio, this approval represents a major advancement in metabolic disorder therapeutics and is expected to contribute significantly to the company’s prescription drug revenue in the coming years
